Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination

被引:71
作者
Griffin, Roger J.
Henderson, Andrew
Curtin, Nicola J.
Echalier, Aude
Endicott, Jane A.
Hardcastle, Ian R.
Newell, David R.
Noble, Martin E. M.
Wang, Lan-Zhen
Golding, Bernard T.
机构
[1] Univ Newcastle, Sch Nat Sci Chem, No Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Univ Newcastle, Sch Med, No Ins Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[3] Univ Oxford, Lab Mol Biophys, Oxford OX1 3QU, England
[4] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England
关键词
D O I
10.1021/ja060595j
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
β-Piperidinoethylsulfides are oxidized by m-chloroperbenzoic acid to intermediates containing both N-oxide and sulfone functions. These undergo a Cope-type elimination to a vinylsulfone that can be captured by amines to afford β-aminoethylsulfones. When a β-aminoethylsulfone group is linked to the 4-position of a phenyl group attached at N-2 of O6-cyclohexylmethylguanine, the resulting derivatives are inhibitors of the cyclin-dependent kinase CDK2. One of the most potent inhibitors (IC50 = 45 nM) contained a N-3-hydroxypropyl group on the aminoethylsulfonyl substituent. The crystal structure of this inhibitor bound to CDK2/cyclin A was determined and shows an unusual network of hydrogen bonds. The synthetic methodology developed can be utilized in multiple-parallel format and has numerous potential applications in medicinal chemistry. Copyright © 2006 American Chemical Society.
引用
收藏
页码:6012 / 6013
页数:2
相关论文
共 13 条
[1]   Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].
Arris, CE ;
Boyle, FT ;
Calvert, AH ;
Curtin, NJ ;
Endicott, JA ;
Garman, EF ;
Gibson, AE ;
Golding, BT ;
Grant, S ;
Griffin, RJ ;
Jewsbury, P ;
Johnson, LN ;
Lawrie, AM ;
Newell, DR ;
Noble, MEM ;
Sausville, EA ;
Schultz, R ;
Yu, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2797-2804
[2]   THERMAL DECOMPOSITION OF AMINE OXIDES TO OLEFINS AND DIALKYLHYDROXXYLAMINES [J].
COPE, AC ;
FOSTER, TT ;
TOWLE, PH .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1949, 71 (12) :3929-3935
[3]   Issues and progress with protein kinase inhibitors for cancer treatment [J].
Dancey, J ;
Sausville, EA .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :296-313
[4]   Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor [J].
Davies, TG ;
Bentley, J ;
Arris, CE ;
Boyle, FT ;
Curtin, NJ ;
Endicott, JA ;
Gibson, AE ;
Golding, BT ;
Griffin, RJ ;
Hardcastle, IR ;
Jewsbury, P ;
Johnson, LN ;
Mesguiche, V ;
Newell, DR ;
Noble, MEM ;
Tucker, JA ;
Wang, L ;
Whitfield, HJ .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (10) :745-749
[5]   Recent progress in the discovery and development of cyclin-dependant kinase inhibitors [J].
Fischer, PM ;
Gianella-Borradori, A .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (04) :457-477
[6]  
Fischer PM, 2004, CELL CYCLE, V3, P742
[7]   N2-substituted O6-cyclohexylmethylguanine derivatives:: Potent inhibitors of cyclin-dependent kinases 1 and 2 [J].
Hardcastle, IR ;
Arris, CE ;
Bentley, J ;
Boyle, FT ;
Chen, YH ;
Curtin, NJ ;
Endicott, JA ;
Gibson, AE ;
Golding, BT ;
Griffin, RJ ;
Jewsbury, P ;
Menyerol, J ;
Mesguiche, V ;
Newell, DR ;
Noble, MEM ;
Pratt, DJ ;
Wang, LZ ;
Whitfield, HJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (15) :3710-3722
[8]   Designing inhibitors of cyclin-dependent kinases [J].
Hardcastle, IR ;
Golding, BT ;
Griffin, RJ .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :325-348
[9]  
Henderson A, UNPUB
[10]   Pharmacological inhibitors of cyclin-dependent kinases [J].
Knockaert, M ;
Greengard, P ;
Meijer, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (09) :417-425